Changing standard of care during a randomized trial: examples, considerations and guidelines
- 24 January 2026
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1046-1053
Abstract
Improvements in cancer treatment are guided by randomized clinical trials (RCTs) that reliably assess the therapeutic impact of adding experimental treatments into clinical practice. The fundamental value of RCTs is that the difference in outcomes between the experimental and control arms provides an unbiased estimate of the risk-benefit ratio for the experimental treatment. However, the clinical relevance of trial results depends on the control arm accurately reflecting the appropriate standard of care (SOC) in the intended-use population. Due to the accelerating pace of cancer treatment development, it is becoming more common for the SOC to change during an ongoing randomized trial. This increasingly dynamic SOC landscape may have a nontrivial impact on the conduct and interpretation of future RCTs, and thus it is important to appreciate these issues and, when possible, prospectively address them when designing and conducting clinical trials. We review common scenarios where the SOC changes and provide recommendations on how to design a trial to minimize the impact of such changes when the trial is ongoing.Keywords
This publication has 38 references indexed in Scilit:
- When suboptimal post-protocol care in oncology trials is rewardedEuropean Journal of Cancer, 2025
- Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trialsThe Lancet Oncology, 2025
- Re: Adjuvant Pembrolizumab Versus Observation in Muscle-Invasive Urothelial CarcinomaEuropean Urology, 2024
- The fate of sotorasib: a regulatory failure potentially harming patientsThe Lancet Oncology, 2024
- Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the futureAnnals of Oncology, 2022
- Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICsThe Lancet Regional Health - Americas, 2022
- Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical TrialsJAMA Network Open, 2021
- Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug AdministrationJAMA Internal Medicine, 2020
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015